期刊文献+

罗格列酮对胰岛素抵抗大鼠血一氧化氮和内皮素的影响 被引量:2

Effects of Rosiglitazone on the Levels of Nitric Oxide and Endothelin in Rats with Insulin Resistance
在线阅读 下载PDF
导出
摘要 目的探讨罗格列酮对胰岛素抵抗大鼠血一氧化氮和内皮素的影响及其可能作用机制。方法采用高果糖饲料诱导SD大鼠建立胰岛素抵抗模型,并以普通饲料喂养作为对照组,4周后分别用与不用罗格列酮处理对照组和模型组。8周末测定各组收缩压、空腹血糖、血胰岛素、血脂、血清一氧化氮和血浆内皮素的含量及主动脉一氧化氮合酶活性。结果模型组收缩压、血胰岛素和血浆内皮素均高于对照组;主动脉一氧化氮合酶活性和一氧化氮含量显著低于对照组,同时出现脂质代谢紊乱。罗格列酮能显著降低模型组收缩压、血胰岛素和血浆内皮素;提高主动脉一氧化氮合酶活性和一氧化氮含量;改善胰岛素抵抗及脂质代谢紊乱,但罗格列酮不影响对照组大鼠上述各项指标。结论罗格列酮能改善胰岛素抵抗大鼠血管内皮功能,其机制可能是:一方面通过降低血压、提高胰岛素的敏感性、改善脂质代谢紊乱;另一方面通过提高主动脉一氧化氮合酶活性促进主动脉一氧化氮释放,同时抑制内皮素的增加。 Aim To investigate the effect of rosiglitazone on the blood levels of nitric oxide (NO)andendothelin-1 (ET- 1) in insulin resistant rats and the underlying mechanism. Methods Male Sprague-Dawley (SD) rats were fed with high fructose to induce insulin resistant rats model, rats were treated with or without rosiglitazone after 4 weeks. At the end of 8th week, systolic blood pressure (SBP), fasting blood sugar (FBS), fasting serum insulin (PSI), blood lipids, NO, ET- 1 and aortic nitric oxide synthase (NOS ) activity were meastured respectively in groups. Results Compared with control group, SBP, FSI and ET-1 in model group significantly increased; aortic NOS activity and NO levels were significantly lowered. At the same time, the abnormity of lipid metabolism appeared in the model group. After rosiglitazone treatment, SBP, FSI and ET-1 remarkably reduced; aortic NOS activity and NO levels significantly increased; insulin resistance and the abnoimity of lipid metabolism were improved. While all indexes did not change significantly after rosiglitazone treated control rats. Conclusions Rosiglitazone may improve vascular endothelial function in rats with insulin resistance by decreasing blood pressure, increasing insulin sensitivity, improving the abnoimity of lipid metabolism, besides, it could be associated with nitric oxide elevating by increasing nitric oxide synthase activity and inhibiting endothelin increasing.
出处 《中国动脉硬化杂志》 CAS CSCD 2005年第5期557-559,共3页 Chinese Journal of Arteriosclerosis
基金 湖南省自然科学基金(01JJY2147)资助
关键词 药理学 胰岛素抵抗 放射免疫法 一氧化氮 内皮素1 血管内皮功能 罗格列酮 Nitric Oxide Endothelin-1 Vascular Endothelial Function Rosiglitazone Insulin Resistance Nitric Oxide Synthase
作者简介 凌宏艳.博士研究生。讲师。研究方向为心血管药理。E-mail为linesman0203@126.com。 通讯作者胡弼,教授。主要研究方向为心血管生理,E-mail为Hu50Bi@hotmail.com。
  • 相关文献

参考文献14

  • 1Walker AB, Chattington PD, Buckingham RE, Williams G. The thiazolidinedione rosiglitazone (BRL-49653) lowers blood pressure and protects against impairment of endothelial function in Zucker fatty rats. Diabetes, 1999, 48: 1 448-453.
  • 2Diep QN, Mabrouk ME1, Cohn JS, Endemann D, Amiri F, Virdis A, et al. Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin Ⅱ-infused rats: Role of peroxisome proliferator-activated receptor-. Circulation, 2002, 105: 2 296-302.
  • 3Raji A, Seely EW, Bekins SA, Williams GH, Simonson DC. Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients. Diabetes Care, 2003, 26 (1): 172-178.
  • 4Iglarz M, Touyz RM, Amiri F, Lavoie MF, Diep QN, Schiffrin EL. Effect of peroxisome proliferator-activated receptor- and activators on vascular remodeling in endothelin-dependent hypertension. Arterioscler Thromb Vasc Biol, 2003, 23: 45-51.
  • 5王敏哲,马琳,李旭芳,李晓岚,马耘,莫颖.罗格列酮改善2型糖尿病患者血管内皮功能的临床观察[J].现代医学,2004,32(3):190-192. 被引量:9
  • 6Calnek DS, Mazzella L, Roser S, Roman J, Hart CM. Peroxisome proliferator-activated receptor ligands increase release of nitric oxide from endothelial cells. Arterioscler Thromb Vasc Biol, 2003, 23: 52-57.
  • 7Fukunaga Y, Itoh H, Doi K, Tanaka T, Yamashita J, Chun TH, et al. Thiazolidinediones, peroxisome proliferator-activated receptor gamma agonists, regulate endothelial cell growth and secretion of vasoactive peptides. Atherosclerosis, 2001, 158 (1): 113-119.
  • 8Reaven GM, Hwang IS, Ho H. Fructose induced insulin resistance and hypertension in rats. Hypertension, 1987, 10: 512.
  • 9李光伟 潘孝仁.检测人群胰岛素敏感性一项新指标[J].中华内分泌代谢杂志,1998,37:390-392.
  • 10Shinozaki K, Kashiwagi A, Masada M, Okamura T. Stress and vascular responses: oxidative stress and endothelial dysfunction in the insulin-resistant state. J Pharmacol Sci, 2003, 91 (3): 187-191.

二级参考文献24

  • 1李光伟,Step.,L.检测人群胰岛素敏感性的一项新指数[J].中华内科杂志,1993,32(10):656-660. 被引量:2126
  • 2陈达光,林金秀,曾开淇,郑舒亮,黄端,李宝彬.肥胖和高血压病患者胰岛素敏感性的变化[J].中华医学杂志,1996,76(7):519-523. 被引量:44
  • 3[1]Parulkar AA,Pendergrass ML,Granda-Ayala R,et al.Nonhypoglycemic effects of thiazolidinediones[J].Ann Intern Med,2001;134:61-71.
  • 4[2]Raji A,Seely EW,Bekins SA,et al.Rosiglitazone improves insulinsensitivity and lowers blood pressure in hypertensive patients[J].Diabetes Care,2003;26(1):172-178.
  • 5[3]Walker AB,Chattington PD,Buckingham RE,et al.Thethiazolidinedione rosiglitazone (BRL-49653)lowers blood pressure and protects against impairment of endothelial function in Zucker fatty rats[J].Diabetes,1999;48:1448-1453.
  • 6[4]Haffner SM,Miettinen H,Stern MP.The homeostasis model in theSan Antonio Heart Study[J].Diabetes Care,1997;20:1087-1092.
  • 7[5]Celermajer DS,Sorensen KE,Gooch VM,et al.Non-invasivedetection of endothelial dysfunction in children and adults at risk of atherosclerosis[J].Lancet,1992;340:1111-1115.
  • 8[6]Vanhoutte PM.Ageing and endothelial dysfunction[J].Eur HeartJ Supplements,2002;4(Suppl A):A8-A17.
  • 9[7]Arcaro G,Cretti A,Balzano S,et al.Insulin causes endothelialdysfunction in humans.Sites and mechanisms[J].Circulation,2002;105:576-582.
  • 10[8]Diep QN,Mabrouk ME,Cohn JS,et al.Structure,endothelialfunction,cell growth,and inflammation in blood vessels of angiotensin Ⅱ-infused rats.Role of peroxisome proliferator-activated receptor-γ[J].Circulation,2002;105:2296-2302.

共引文献13

同被引文献33

  • 1杨义生,陈家伦.脂肪组织分泌功能研究新进展[J].中国糖尿病杂志,2004,12(3):228-230. 被引量:14
  • 2孔宪如,董吉祥,徐志刚,史光英.匹格列酮对2型糖尿病炎症标志物的影响研究[J].江苏医药,2004,30(9):674-675. 被引量:7
  • 3都健,赵晓娟,刘国良.胰岛素抵抗大鼠内皮依赖性血管舒张功能研究[J].中华内分泌代谢杂志,2003,19(4):313-316. 被引量:23
  • 4林华,王颖彦.4种口服降糖药治疗2型糖尿病的成本-效果分析[J].安徽医药,2006,10(8):634-635. 被引量:13
  • 5Haverkate F, Thompson SG, Pyke SM, et al. Production of C reactive protein and risk of coronary events in stable and unstable angina [ J ]. Lancet, 1997,349:462 - 6.
  • 6Pradhan AI, Manson JE, Nader R, et al. C-reactive protein, interlerkin-6,and risk of developing type 2 diabetes mellitus [ J ]. JAMA, 2001,286:327 - 34.
  • 7Paseerl V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells [ J ]. Circulation, 2003,102:2165 - 7.
  • 8Venugopai SK, Devalaj S, YuhannaI, et al. Demonstration that C-reactive protein decrease eNOS expression and bioactivity in human aorticendothelial cells [ J ]. Circulation,2003,106 : 1439 - 41.
  • 9Andre-SchmutzI, Hindelang C, Benoist C,et al. Cellular and molecular changes accompanying the progression from insulitis to diabetes [ J]. Eur J Immunol, 1999,29:245 - 55.
  • 10Cavusoglu Gorenek B, Alpsoy S, et al. Evaluation of C-reactive protein fibrinogen and antithrombin - 2 as risk factor for coronary artery disease[ J]. Isr med Assoc J,2003 : 13 - 6.

引证文献2

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部